Biotest AG, the German producer of diagnostics and pharmaceuticals based on human blood, has reported a 7.6% rise in 1995 sales to 307.9 million Deutschemarks ($208.3 million), helped by a recovery in the German domestic market, where turnover expanded by 14.3% to 136.3 million marks.
Foreign sales rose 2.9% to 171.6 million marks. Pharmaceutical sales alone expanded by 13.3% to 192.7 million marks, while diagnostics turnover dipped slightly to 111.52 million marks. Group net profits increased by 23.6% to reach 11 million marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze